Compare EIC & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIC | SENS |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 213.2M |
| IPO Year | N/A | 2014 |
| Metric | EIC | SENS |
|---|---|---|
| Price | $10.75 | $5.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $12.63 | ★ $18.38 |
| AVG Volume (30 Days) | 145.0K | ★ 1.1M |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 13.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | N/A | $74.15 |
| Revenue Next Year | N/A | $58.60 |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $9.17 | $0.41 |
| 52 Week High | $14.80 | $8.75 |
| Indicator | EIC | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 71.31 | 45.77 |
| Support Level | $9.25 | $5.26 |
| Resistance Level | $11.34 | $8.55 |
| Average True Range (ATR) | 0.20 | 0.48 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 87.85 | 36.46 |
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.